Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Epizyme (EPZM) Share Price
News headlines about Epizyme (NASDAQ:EPZM) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Epizyme earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6903107550788 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Epizyme (NASDAQ:EPZM) opened at 18.90 on Friday. The stock’s market capitalization is $1.11 billion. Epizyme has a 52-week low of $8.38 and a 52-week high of $20.45. The company’s 50-day moving average price is $17.26 and its 200 day moving average price is $15.44.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.95 million. The business’s quarterly revenue was up 2027.7% on a year-over-year basis. During the same period last year, the business earned ($0.49) EPS. On average, equities research analysts anticipate that Epizyme will post ($2.36) earnings per share for the current year.
EPZM has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, July 12th. Cann reiterated a “buy” rating and set a $26.00 target price on shares of Epizyme in a research report on Wednesday, June 21st. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Monday, June 12th. Finally, Citigroup Inc. boosted their target price on Epizyme from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, June 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Epizyme presently has an average rating of “Buy” and a consensus target price of $23.33.
In other news, Director David M. Mott acquired 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at $91,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction on Monday, July 24th. The shares were sold at an average price of $13.44, for a total value of $201,600.00. Following the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at approximately $298,744.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,000 shares of company stock valued at $688,950. 25.20% of the stock is currently owned by insiders.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.